Indication: Solid Tumors

A Phase 2/3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia with Plinabulin Versus Pegfilgrastim in Patients with Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy

Adv./Metastatic NSCLC/Breast/Hormone RefraProstate

Sub-indication: NSCLC; Hormone refractory mCRPC

Line of Therapy: NSCLC given in conjunction with 2d line tx-docetaxel (previously received platinum or intolerant, or would benefit from docetaxel)

Drug Study

Principal Investigator: Arash Rezazadeh, M.D.
Norton Cancer Institute

Sponsor: Beyond Spring

Learn more at ClinicalTrials.gov

Email for more information: CancerResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.